



Development of Peptide-Based Drugs for Alzheimer's Disease

Guest Editor:

Dr. Anne Kasus-Jacobi

University of Oklahoma Health
Sciences Center, Oklahoma City,
United States

Deadline for manuscript
submissions:

closed (31 July 2022)

Message from the Guest Editor

Peptides represent a unique class of pharmaceutical compounds, between small molecules and proteins. This immense source of bioactive compounds offers great potential to solve previously hard-to-address oncological, metabolic, infectious, and neurodegenerative diseases. Remarkable advantages of peptides, such as their versatility, ability to disrupt interaction between macromolecules, and specificity for one or multiple targets, enables innovative approaches to the most challenging conditions. In addition, during the past decade, typical limitations to the pharmacological utilization of peptides (short half-life, low bioavailability, limited brain penetration, high production cost) have been and continue to be overcome by major breakthroughs in peptide chemistry.

This Special Issue intends to illustrate how peptide-based therapeutics are being developed for Alzheimer's disease as an alternative approach to small molecule or antibody drugs, to address this unresolved public health priority.

We look forward to reading your original research article or up-to-date review contribution.





an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Peter E. Nielsen

Department of Cellular and
Molecular Medicine, Faculty of
Health and Medical Sciences,
University of Copenhagen,
Blegdamsvej 3C, DK-2200
Copenhagen, Denmark

Prof. Dr. Lukasz Kurgan

Department of Computer
Science, Virginia Commonwealth
University, Richmond, VA 23284,
USA

Message from the Editorial Board

Biomolecules is a multidisciplinary open-access journal that reports on all aspects of research related to biogenic substances, from small molecules to complex polymers. We invite manuscripts of high scientific quality that pertain to the diverse aspects relevant to organic molecules, irrespective of the biological question or methodology. We aim for a competent, fair peer review and rapid publication. Please look at some of the exciting work that has been published in *Biomolecules* so far. We would be delighted to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Biochemistry)

Contact Us

Biomolecules Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomolecules
biomolecules@mdpi.com
X@Biomol_MDPI